

## Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2015

**Authors:** W. Siala<sup>1</sup>, P. Fernandes<sup>2</sup>, PM Tulkens<sup>1</sup>, F. Van Bambeke<sup>1</sup>

**Background:** FUS is currently evaluated as an oral drug for the treatment of cSSSTI in which biofilms play a major role. We evaluated the activity of FUS alone or combined with other antistaphylococcal antibiotics (DAP, VAN, LZD) in an *in vitro* pharmacodynamic model of staphylococcal biofilm using the CDC reactor system, exposing biofilms to shear forces and mimicking antibiotic pharmacokinetics.

**Methods:** Biofilms of *S. aureus* ATCC25923 were grown at 37°C on polycarbonate coupons inserted into rods contained in the CDC biofilm reactor using a starting inoculum of 10<sup>5</sup> CFU/ml. Preconditioning was achieved in TSB + 1% glucose and 2%NaCl by 6h batch incubation followed by 14h of continuous flow (11.6 mL/min). Antibiotics were then injected at concentrations corresponding to their human fC<sub>max</sub>, with flow rates adapted to simulate their respective half-lives. Coupons were collected over time and washed in PBS. Bacteria were recovered by 3 alternating 60-s cycles of vortexing and sonication, and plated for CFU counting.

**Results:** FUS alone had no activity while VAN, LZD and DAP alone caused a minimal decrease in CFU (0.5-0.7 log). Combinations of FUS with DAP or LZD were highly synergistic, reaching 2.45 and 3.97 log<sub>10</sub> CFU decrease compared to control, respectively. In contrast, combining FUS with VAN did not markedly improve activity on biofilms.

**Conclusion:** Combinations of FUS with DAP or LZD were the most effective against *S. aureus* biofilm in this pharmacodynamic model, warranting testing *in vivo*.